Q1/23 Talicia net revenues of $3.4 million; Cash balance of $28.8 million as of March 31, 2023[1]; Extinguishment of all debt obligations in exchange for the...

Related Keywords

United States , United Kingdom , Israel , American , Redhill Biopharma , Adi Frish , Dror Ben Asher , National Institutes Of Health , Development Expenses , Trademark Office , Company American Depositary Shares Adss , European Patent Office , Collateral Management , Nasdaq , Movantik Acquisition Co , Product Development Pipeline , Exchange Commission , Company Expanded Access Program , Talicia Warranty Program , International Journal Of Molecular Sciences , Redhill Biopharma Ltd , International Journal Of Infectious Diseases , Nuclear Countermeasures Program , Company Annual Report On Form , Nasdaq Stock Market , Nuclear Medical Countermeasures Acute Radiation Syndrome , Company Adss , Redhill Biopharma Inc , Us Army , Business Development , Kukbo Co , National Institute Of Allergy , Regulatory Agency , National Institutes , Acute Radiation Syndrome , Hill Biopharma , Chief Executive Officer , Net Revenues , Administrative Expenses , Financial Income , Net Loss , Trade Receivables , Cash Used , Operating Activities , Cash Provided , Financing Activities , Market Value , Publicly Held Shares , Nasdaq Rules , Listing Rule , Nasdaq Listing Rule , Nasdaq Capital , American Depositary Shares , Subscription Agreement , Exclusive License Agreement , Digestive Diseases Week , Infectious Disease Product , Medical Countermeasures , National Institute , Infectious Diseases , Animal Rule , Priority Review , International Journal , Marketing Authorisation Application , United Kingdom Medicines , Nontuberculous Mycobacteria , Private Securities Litigation Reform Act , Development Pipeline , Expanded Access Program , Annual Report , Capital Deficiency , Warranty Program , Radiation Toxicity , Homeland Security ,